The present invention relates to catheters, particularly, catheters designed for improved performance in a loco-regional perfusion system.
Gene therapy and cell therapy techniques in the treatment have attracted increased attention due to their potential to be uniquely tailored and efficacious in addressing the root cause pathogenesis of various conditions. Nevertheless, issues related to delivery, including vector efficiency, dose, specificity, and safety remain. As such, there is a need for further research directed to ways of achieving a more targeted, homogenous delivery of drugs suitable for treatment of various conditions. In addition, there is a need for improved devices to facilitate local delivery of gene therapy drugs into the body to treat target organs, for example, by isolating the target organs from the systemic circulation.
The above and other features of the present disclosure, their nature, and various advantages will become more apparent upon consideration of the following detailed description, taken in conjunction with the accompanying drawings, in which:
The following presents a simplified summary of various aspects of the present disclosure in order to provide a basic understanding of such aspects. This summary is not an extensive overview of the disclosure. It is intended to neither identify key or critical elements of the disclosure, nor delineate any scope of the particular embodiments of the disclosure or any scope of the claims. Its sole purpose is to present some concepts of the disclosure in a simplified form as a prelude to the more detailed description that is presented later.
One aspect of the present disclosure relates to a recovery catheter comprising: a lumen shaft having a proximal end and a distal end; an expandable balloon structure disposed near the distal end of the lumen shaft; and a tip portion between the balloon structure and the distal end of the lumen shaft. In at least one embodiment, the recovery catheter is configured to support a liquid flow rate of about 150 mL/min or greater, or about 400 mL/min or greater.
In at least one embodiment, the tip portion comprises an elongated shaft extending from the balloon portion to the distal end of the lumen shaft. In at least one embodiment, the tip comprises a distal opening at the distal end and a plurality of perforations along the elongated shaft. In at least one embodiment, the length of the elongated shaft of the tip portion is from about 2 mm to about 35 mm, about 5 mm to about 30 mm, about 10 mm to about 25 mm, or about 15 mm to 25 mm.
In at least one embodiment, an inner diameter of the lumen shaft is at least about 2 mm.
In at least one embodiment, an expanded diameter of the balloon structure is from about 15 mm to about 30 mm, about 15 mm to about 20 mm, about 20 mm to about 25 mm, about 24 mm to about 28 mm, or about 25 mm to about 30 mm.
In at least one embodiment, the lumen shaft is a multi-lumen shaft comprising at least two lumen shafts.
In at least one embodiment, the multi-lumen shaft comprises an inner lumen shaft and an outer lumen shaft that at least partially encompasses the inner lumen shaft to expose a proximal portion of the inner lumen shaft near the proximal end of the lumen shaft. In at least one embodiment, the balloon structure and the tip portion are disposed on the inner lumen shaft.
In at least one embodiment, the recovery catheter is a multi-balloon catheter further comprising at least an additional expandable balloon structure disposed adjacent to the primary balloon structure. In at least one embodiment, an expanded diameter of the additional balloon structure is greater than an expanded diameter of the primary balloon structure. In at least one embodiment, a portion of the lumen shaft between the balloon structures comprises one or more perforations.
In at least one embodiment, the recovery catheter further comprises: a stent structure disposed on a portion of the lumen shaft between the tip portion and the balloon structure.
In at least one embodiment, the recovery catheter further comprises: perforations along the lumen shaft between the balloon structure and the stent structure and/or between the stent structure and the distal end.
Another aspect of the present disclosure relates to a recovery catheter comprising: a lumen shaft having a proximal end and a distal end; a covered disk-shaped stent structure disposed near the distal end of the lumen shaft; and a tip portion between the covered disk-shaped stent structure and the distal end of the lumen shaft. In at least one embodiment, the recovery catheter is configured to support a liquid flow rate of about 150 mL/min or greater, or about 400 mL/min or greater.
In at least one embodiment, the tip portion comprises a radio marker or a radiopaque filler composition.
Another aspect of the present disclosure relates to a recovery catheter comprising: a lumen shaft having a proximal end and a distal end; and a deployable stent structure disposed at the distal end of the lumen shaft, the stent structure comprising a covering on a proximal portion. In at least one embodiment, the stent structure, when deployed, is uncovered at a distal portion. In at least one embodiment, the recovery catheter is configured to support a liquid flow rate of about 150 mL/min or greater, or about 400 mL/min or greater.
In at least one embodiment, any of the foregoing recovery catheters are configured to support a liquid flow rate of at least about 150 mL/min, at least about 200 mL/min, at least about 250 mL/min, at least about 300 mL/min, at least about 350 mL/min, at least about 400 mL/min, at least about 450 mL/min, at least about 500 mL/min, at least about 550 mL/min, at least about 600 mL/min, at least about 650 mL/min, at least about 700 mL/min, at least about 750 mL/min, at least about 800 mL/min, at least about 850 mL/min, at least about 900 mL/min, at least about 950 mL/min, or at least about 1000 mL/min. In at least one embodiment, any of the foregoing catheters are configured to support a liquid flow rate of about 150 mL/min to about 1000 mL/min.
Another aspect of the present disclosure relates to a perfusion catheter comprising: a lumen shaft having a proximal end and a distal end; an occlusion structure near the distal end of the lumen shaft, the occlusion structure adapted to seal perfused blood from systemic blood circulation when inserted into a vascular blood vessel; and a tip portion comprising an elongated shaft extending from the occlusion structure to the proximal end of the lumen shaft, the tip comprising a proximal opening at the proximal end. In at least one embodiment, the occlusion structure is selected from: a balloon; a plug configurable between a retracted state and an extended state; a wedge shaped to adapt to a vessel or ostium; a releasable covered stent; and a releasable braided disk. In at least one embodiment, the perfusion catheter is configured to support a liquid flow rate of about 150 mL/min or greater, or about 400 mL/min or greater.
In at least one embodiment, the occlusion structure comprises the plug configurable between a retracted state and an extended state. In at least one embodiment, when in the extended state, a portion of the plug extends distally from the tip portion.
In at least one embodiment, the occlusion structure comprises the releasable covered stent. In at least one embodiment, the lumen shaft comprises an outer sheath that covers the releasable covered stent. In at least one embodiment, when the sheath is retracted proximally, the releasable covered stent is deployed past the distal end of the lumen shaft having an expanded diameter that is greater than the diameter of the lumen shaft.
In at least one embodiment, the occlusion structure comprises the releasable braided disk. In at least one embodiment, the lumen shaft comprises an outer sheath that covers the releasable braided disk. In at least one embodiment, when the sheath is retracted proximally, the releasable braided disk is deployed having an expanded diameter that is greater than the diameter of the lumen shaft. In at least one embodiment, the tip portion extends distally past the releasable braided disk when deployed.
In at least one embodiment, any of the foregoing perfusion catheters are configured to support a liquid flow rate of at least about 150 mL/min, at least about 200 mL/min, at least about 250 mL/min, at least about 300 mL/min, at least about 350 mL/min, at least about 400 mL/min, at least about 450 mL/min, at least about 500 mL/min, at least about 550 mL/min, at least about 600 mL/min, at least about 650 mL/min, at least about 700 mL/min, at least about 750 mL/min, at least about 800 mL/min, at least about 850 mL/min, at least about 900 mL/min, at least about 950 mL/min, or at least about 1000 mL/min.
As used herein, the singular forms “a,” “an,” and “the” include plural references unless the context clearly indicates otherwise. Thus, for example, reference to “a drug” includes a single drug as well as a mixture of two or more different drugs.
Also as used herein, “about,” when used in connection with a measured quantity, refers to the normal variations in that measured quantity, as expected by one of ordinary skill in the art in making the measurement and exercising a level of care commensurate with the objective of measurement and the precision of the measuring equipment. In certain embodiments, the term “about” includes the recited number ±10%, such that “about 10” would include from 9 to 11.
Also as used herein, “perfusion,” “perfused,” and “perfusing” have their ordinary and customary meaning in the art and refer to administration for a time period (typically a minute or more) that is substantially longer than the art recognized term of “injection” or “bolus injection” (typically less than a minute). The flow rate of the perfusion will depend at least in part on the volume administered.
Also as used herein, “isolated,” “substantially isolated,” “largely isolated,” and their variants are terms that do not require complete or absolute isolation of the renal or systemic circulation; rather, they are intended to mean that a majority, preferably the major part or even substantially all of the specified circulation is isolated. Also as used herein, “partially isolated” refers to any nontrivial portion of the specified circulation being isolated.
Also as used herein, “non-naturally restricted” includes any method of restricting the flow of fluid through a blood vessel, e.g., balloon catheter, sutures, etc., but does not include naturally occurring restriction, e.g., plaque build-up (stenosis). Non-natural restriction includes substantial or total isolation of, for example, the renal circulation.
Also as used herein, “minimally invasive” is intended to include any procedure that does not require open surgical access to the kidney or vessels closely associated with the kidney. Such procedures include the use of endoscopic means to access the kidney, and also catheter-based means relying on access via large arteries and veins.
Also as used herein, a “patient” refers to a subject, particularly a human (but could also encompass a non-human), who has presented a clinical manifestation of a particular symptom or symptoms suggesting the need for treatment, who is treated prophylactically for a condition, or who has been diagnosed with a condition to be treated.
Also as used herein, a “subject” encompasses the definition of the term “patient” and does not exclude individuals who are otherwise healthy.
Also as used herein, “treatment of” and “treating” include the administration of a drug with the intent to lessen the severity of or prevent a condition, e.g., a renal condition or renal disease.
Also as used herein, an “active agent” refers to any material that is intended to produce a therapeutic, prophylactic, or other intended effect, whether or not approved by a government agency for that purpose.
Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to illuminate certain materials and methods and does not pose a limitation on scope. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosed materials and methods.
Certain embodiments of the present disclosure are directed to catheters for use in loco-regional perfusion (LRP) systems. The catheters are designed for high liquid flow rates through organs in which LRP is to be performed, while providing improved sealing and isolation of the LRP circuit and stability for catheter positioning during perfusion and recovery of the perfusate.
LRP may be performed in various bodily organs including, but not limited to, the heart, the kidneys, and the liver. Exemplary systems to perform an LRP procedure in an unarrested beating heart are described in International Application No. PCT/IB2020/000692, filed Aug. 26, 2020, and International Application No. PCT/EP2022/054361, filed Feb. 22, 2022, the disclosures of which are hereby incorporated by reference herein in their entireties. The coronary circulation provides blood supply to the tissue of the heart, in which there are a number of coronary arteries. Normally, four main coronary arteries provide oxygenated blood to the heart for distribution throughout the heart tissue: the left main and right coronary arteries, the left anterior descending artery, and the left circumflex artery. Oxygen depleted blood flows through the coronary sinus.
An exemplary LRP procedure for the heart involves isolating the coronary circulation of a patient from the systemic circulation of the patient by forming a closed circuit through the coronary circulation that includes a first perfusion catheter connected to a supply line, a second perfusion catheter connected to the supply line, a recovery catheter connected to a return line, and an external membrane oxygenation device. In an exemplary system, each perfusion catheter is inserted into a coronary artery, and the recovery catheter is inserted into the coronary sinus. A perfusate comprising a drug suitable for treatment of a heart condition can be delivered to the heart muscle while substantially isolating the patient's coronary circulation from the patient's systemic circulation with the closed circuit.
An exemplary LRP procedure for the kidney involves positioning a perfusion catheter in the renal artery of the kidney and positioning a recovery catheter in the renal vein of the kidney. A closed circuit is created by the perfusion catheter and the recovery catheter in combination with a membrane oxygenation device. A perfusate is then flowed through the closed circuit in the renal circulation, which is substantially isolated from the systemic circulation of the patient. An additional recovery catheter can be inserted into the bladder to measure urine excretion during the perfusion. An exemplary system to perform an LRP procedure in a kidney is described in International Application No. PCT/EP2022/054360, filed Feb. 22, 2022, the disclosure of which is hereby incorporated by reference herein in its entirety.
An exemplary LRP procedure for the liver involves positioning a first perfusion catheter in the hepatic artery, positioning a second perfusion catheter in the portal vein, and positioning one or more recovery catheters in the inferior vena cava proximal to the liver. A closed circuit is created by the perfusion catheters and the one or more recovery catheters in combination with one or more membrane oxygenation devices. A perfusate is then flowed through the closed circuit in the hepatic circulation, which is substantially isolated from the systemic circulation of the patient. An exemplary system to perform an LRP procedure in a liver is described in International Application No. PCT/EP2022/054356, filed Feb. 22, 2022, the disclosure of which is hereby incorporated by reference herein in its entirety.
Exemplary recovery catheters and perfusion catheters are now described. While the various catheter embodiments are depicted as being deployed within the heart, it is to be understood that deployment in the heart is merely illustrative. The catheters can be configured for the anatomy of the target organ for which LRP is to be performed, as would be appreciated by those of ordinary skill in the art. Moreover, it is to be understood that any of the catheters described as “recovery catheters” could also be used as “perfusion catheters,” and vice versa. The embodiments described herein are not limited to LRP of a target organ, but may also be used to isolate the circulation of the target organ from the systemic circulation, for example, to reduce or prevent exposure of the target organ to a drug or other agent introduced into the systemic circulation that may have a deleterious effect on the target organ. Those of ordinary skill in the art would appreciate other uses of the catheter embodiments described herein, for example, in applications for which sealing of a blood vessel is desired.
Embodiments of exemplary catheters for use as recovery catheters in an LRP system are now described. In at least one embodiment, the recovery catheters are designed to support a liquid suction flow rate of about 150 mL/min or greater (e.g., about 700 mL/min or greater). For example, in certain embodiments, an exemplary catheter can support an in vitro suction flow rate of about 800 mL/min at about −80 mmHg.
Certain embodiments of the recovery catheters are advantageous for use in the return line of an LRP system used to form a closed-circuit within an unarrested beating heart when inserted into the coronary sinus. The catheters described herein can be designed to satisfy the following criteria: capability to access the coronary sinus via the right internal jugular vein; compatibility with an introducer sheath having an inner diameter of 24 Fr or less; compatibility with a 0.035-inch guidewire or smaller; capability to access, seal, and occlude a coronary sinus having a vessel internal diameter of 6 to 20 mm in a human subject or up to 30 mm in a porcine animal model; the ability to avoid occlusion of prominent side veins (e.g., the middle cardiac vein); and the ability to maintain stable position for at least 60 minutes during an LRP procedure.
In certain embodiments, one or more of the catheters may be multi-lumen catheters, such as double-lumen catheters. In certain embodiments, the multi-lumen catheters allow for liquid flow (e.g., a perfusate) and enable inflation of one or more balloons. In certain embodiments, one or more of the catheters may be multi-balloon catheters having two or more balloons. In certain embodiments, one or more of the balloons may be deployed or deflated independently.
The catheter 100 includes a tip portion 108 at the distal end 102 and an expandable balloon structure 110 disposed along a portion 112 of the inner lumen shaft 106. In at least one embodiment, the tip portion 108 includes an elongated shaft extending from the balloon structure 110 to the distal end 102. In at least one embodiment, the length of the elongated shaft of the tip portion is from about 2 mm to about 35 mm, about 5 mm to about 30 mm, about 10 mm to about 25 mm, about 15 mm to 25 mm, or within any subrange defined between (e.g., about 2 mm to about 5 mm). In at least one embodiment, the tip portion 108 includes an opening at the distal end 102 and one or more perforations along the elongated shaft. In at least one embodiment, the tip portion is formed from a compliant material that is more flexible than the material of the inner lumen shaft 106.
In at least one embodiment, the inner lumen shaft 106 includes a concentric inner flow path surrounding the liquid flow path. The concentric inner flow path provides a path for gas flow from the balloon structure 110 to a port 114, which can be used to inflate or deflate the balloon depending on the pressure applied at the port 114. In at least one embodiment, an outermost surface of the inner lumen shaft 106 at the portion 112 is removed such that the portion 112 is sealed by the balloon structure 110 to isolate gas flow from the concentric inner flow path to the balloon structure 110. In at least one embodiment, an expanded diameter of the balloon structure is from about 15 mm to about 30 mm, about 15 mm to about 20 mm, about 20 mm to about 25 mm, about 24 mm to about 28 mm, or about 25 mm to about 30 mm.
In at least one embodiment, during deployment, the outer lumen shaft 406 can be moved distally to abut against the deployed balloon structure 410, resulting in additional pressure by the balloon structure 410 against the ostium of the coronary sinus 352 to further stabilize the position of the catheter 400. In at least another embodiment, a wire structure may be utilized to apply pressure to the balloon structure 410. The wire structure, for example, may have a sinusoidal shape that is deployable to an expanded flower-like structure extending radially from the outer lumen shaft 406 or the inner lumen shaft 404. When brought into contact with the balloon structure 410, the wire structure may produce a more even pressure profile across the surface of the balloon structure 410. Prior to deployment, the wire structure may be covered by the outer lumen 406, or may be covered by an additional lumen outside of the outer lumen 406.
Embodiments of exemplary catheters for use as perfusion catheters in an LRP system are now described. In at least one embodiment, the perfusion catheters are designed to support a liquid perfusion flow rate of 150 mL/min or greater (e.g., about 700 mL/min or greater). In embodiments that utilize multiple perfusion catheters (e.g., insertion of a first catheter into the right coronary artery and insertion of a second catheter into the left coronary artery) can support a combined flow capacity of 700 mL/min or greater.
Certain embodiments of the recovery catheters are advantageous for use in the supply line of an LRP system used to form a closed-circuit within an unarrested beating heart when inserted into the coronary arteries. The catheters described herein can be designed to satisfy the following criteria: capability of femoral access to the coronary arteries; an outer diameter for coronary artery entry of 8 Fr or less; an outer diameter for occlusion of about 6 mm to about 8 mm; compatibility with a 0.018-inch guidewire and a 0.014-inch pressure wire; and the ability to maintain stable position for at least 60 minutes during an LRP procedure.
In certain embodiments, one or more of the catheters may be multi-lumen catheters, such as double-lumen catheters. In certain embodiments, the multi-lumen catheters allow for liquid flow (e.g., a perfusate) and enable inflation of one or more balloons. In certain embodiments, one or more of the catheters may be multi-balloon catheters having two or more balloons. In certain embodiments, one or more of the balloons may be deployed or deflated independently.
The catheter 1100 includes an expandable balloon structure 1110 disposed along a portion 1112 corresponding to the inner lumen shaft 1106 and a tip portion formed by an additional lumen. In at least one embodiment, the inner lumen shaft 1106 includes a concentric inner flow path surrounding the liquid flow path. The concentric inner flow path provides a path for gas flow from the balloon structure 1110 to a port 1114, which can be used to inflate or deflate the balloon depending on the pressure applied at the port 1114. In at least one embodiment, an outermost surface of the inner lumen shaft 1106 at the portion 1112 is removed such that the portion 1112 is sealed by the balloon structure 1110 to isolate gas flow from the concentric inner flow path to the balloon structure 1110. In at least one embodiment, an expanded diameter of the balloon structure is from about 15 mm to about 30 mm, about 15 mm to about 20 mm, about 20 mm to about 25 mm, about 24 mm to about 28 mm, about 25 mm to about 30 mm, or within any subrange defined therebetween (e.g., about 20 mm to about 28 mm).
The catheter 1200 further includes a plug 1210 near the distal end 1202. In at least one embodiment, the plug 1210 is formed from a flexible material, such as silicone or a foam material. In at least one embodiment, the plug 1210 includes an inner portion 1210A that fits onto the inner lumen shaft 1206 and a flexible outer portion 1210B shaped to be configurable between a retracted state (
The catheter 1300 further includes a wedge 1310 near the distal end 1302, which may be shaped to adapt to a vessel or ostium. In at least one embodiment, the wedge 1310 is formed from a flexible material, such as silicone or a foam material. In at least one embodiment, the outer lumen shaft 1304 may be configured to cover the wedge 1310 prior to deployment.
In the foregoing description, numerous specific details are set forth, such as specific materials, dimensions, processes parameters, etc., to provide a thorough understanding of the present invention. The particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments. The words “example” or “exemplary” are used herein to mean serving as an example, instance, or illustration. Any aspect or design described herein as “example” or “exemplary” is not necessarily to be construed as preferred or advantageous over other aspects or designs. Rather, use of the words “example” or “exemplary” is simply intended to present concepts in a concrete fashion. As used in this application, the term “or” is intended to mean an inclusive “or” rather than an exclusive “or”. That is, unless specified otherwise, or clear from context, “X includes A or B” is intended to mean any of the natural inclusive permutations. That is, if X includes A; X includes B; or X includes both A and B, then “X includes A or B” is satisfied under any of the foregoing instances. Reference throughout this specification to “an embodiment”, “certain embodiments”, or “one embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrase “an embodiment”, “certain embodiments”, or “one embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment.
The present invention has been described with reference to specific exemplary embodiments thereof. The specification and drawings are, accordingly, to be regarded in an illustrative rather than a restrictive sense. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.
This application claims the benefit of priority of U.S. Provisional App. No. 63/312,029, filed on Feb. 20, 2022, the disclosure of which is hereby incorporated by reference herein in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2023/054105 | 2/17/2023 | WO |
Number | Date | Country | |
---|---|---|---|
63312029 | Feb 2022 | US |